摘要
目的探讨普拉克索联合卡左双多巴治疗帕金森病(PD)的有效性、安全性及其对患者神经源性特异性烯醇化酶(NSE)、神经肽Y(NPY)水平、生活质量的影响。方法选取2020年2月至2021年2月我科室收治的74例PD患者为研究对象,采用随机数表法将其分为对照组(37例,卡左双多巴治疗)及观察组(37例,普拉克索联合卡左双多巴治疗)。比较两组的临床治疗效果。结果治疗后,两组的UPDRSⅢ及NMSQuest评分均明显降低,且观察组低于对照组(P<0.05)。治疗后,两组的NSE及NPY水平均明显降低,且观察组低于对照组(P<0.05)。观察组患者的药物不良反应总发生率低于对照组(P<0.05)。治疗后,两组的WHOQOL-BREF各领域评分均提高,且观察组高于对照组(P<0.05)。结论普拉克索联合卡左双多巴治疗PD的疗效显著且安全性高,可减轻患者的临床症状,改善机体的NSE及NPY水平,提高患者的生活质量,值得推广。
Objective To investigate the efficacy and safety of pramipexole combined with carbidopa and levodopa in the treatment of Parkinson's disease(PD)and its influences on neuron-specific enolase(NSE),neuropeptide Y(NPY)levels and quality of life of patients.Methods A total of 74 patients with PD admitted in our department from February 2020 to February 2021 were selected as the research objects.The patients were divided into control group(37 cases,treated with carbamazepine)and observation group(37 cases,treated with pramipexole combined with carbidopa and levodopa)by random number table method.The clinical therapeutic effects of the two groups were compared.Results After treatment,UPDRSⅢ and NMSQuest scores of the two groups significantly decreased,and those of the observation group were lower than the control group(P<0.05).After treatment,NSE and NPY levels of the two groups significantly decreased,and those of the observation group were lower than the control group(P<0.05).The total incidence of adverse drug reactions in the observation group was lower than that in the control group(P<0.05).After treatment,WHOQOL-BREF scores in all areas of the two groups improved,and those of the observation group were higher than the control group(P<0.05).Conclusion Pramipexole combined with carbidopa and levodopa in the treatment of PD has significant efficacy and high safety.It can reduce the clinical symptoms,ameliorate the levels of NSE and NPY,and improve the quality of life of patients,which is worthy of promotion.
作者
关建兵
康蓓
杨小静
GUAN Jianbing;KANG Bei;YANG Xiaojing(Baoji People's Hospital,Baoji 721000;Shaanxi Provincial People's Hospital,Xi'an 710068,China)
出处
《临床医学研究与实践》
2022年第15期15-17,共3页
Clinical Research and Practice
基金
陕西省自然科学基础研究计划项目(No.2020JM-663)
关键词
普拉克索
卡左双多巴
帕金森
pramipexole
carbidopa and levodopa
Parkinson's disease